Guardant Health Inc
Research Guardant Health Inc (GH) on Bullrun: market cap USD 22.04B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 22.04B
- Financial periodQ2 2026
- RevenueUSD 334.98M
- Net income-USD 120.14M
- Free cash flow-USD 69.54M
- Gross margin65.4%
Valuation Snapshot
latest market cap is USD 22.04B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 982.02M | -USD 416.30M | -USD 233.07M | 64.5% | -3.32 | USD 378.20M | USD 1.50B | -USD 99.31M |
| FY2024 | USD 739.02M | -USD 436.40M | -USD 274.94M | 60.8% | -3.56 | USD 525.54M | USD 1.14B | -USD 139.65M |
| FY2023 | USD 563.95M | -USD 479.40M | -USD 345.46M | 59.7% | -4.28 | USD 1.13B | USD 1.35B | USD 158.68M |
| FY2022 | USD 449.54M | -USD 654.60M | -USD 386.92M | n/a | -6.41 | USD 141.65M | USD 1.38B | USD 60.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 22.04B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.34B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.79B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.28B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.79B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 10.18B | n/a | n/a | n/a |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Guardant Health Inc's market cap?
Guardant Health Inc's market capitalization is USD 22.04B.
What does Guardant Health Inc do?
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.